Navigation Links
Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
Date:3/13/2008

lar uptake.

In July 2007, Silence Therapeutics formed a research and development collaboration with AstraZeneca to develop AtuRNAi against five specific targets including those in respiratory indications. The Company's AtuRNAi technology also has been sublicensed to Pfizer through Quark's license to Pfizer of the compound RTP-801i-14 for the treatment of Age-related Macular Degeneration (AMD) and a number of other indications. This compound entered the clinic in early 2007. Silence Therapeutics also has licensed to Quark rights to the AtuRNAi structure for its proprietary compound AKIi-5. This compound is in a Phase I human clinical study for treatment of acute kidney injury. In addition, Silence Therapeutics expects to begin the clinical development of its own proprietary AtuRNAi therapeutic molecules for systemic cancer indications in 2008.

Silence Therapeutics is based in London, UK, and Berlin, Germany, and is listed on AIM.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $29.55 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

For more information about AstraZeneca please visit: http://www.astrazeneca.com

About RNAi

RNA interference (RNAi), a Nobel Prize winning technology, is one of the most exciting areas of drug discovery today. This is because it represents a completely new approach to selectively 'silence' or inactivate disease relevant genes and as such it has the potential to create a new class of therapeutic products.


'/>"/>
SOURCE Silence Therapeutics plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
2. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
3. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
4. Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
5. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
6. Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
7. Nile Therapeutics to Announce 2007 Fourth Quarter and Full Year Financial Results on Thursday, March 13, 2008
8. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
9. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
10. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
11. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, Inc., the ... relaunch of his highly informative blog, now named Stem Cells ... are Stem Cells ?” Dr. Harman’s purpose for blogging ... basics of stem cell therapy so that pet owners can ... when considering regenerative medicine. , A veterinarian by trade, Dr. ...
(Date:7/10/2014)... , July 10, 2014  Franciscan ... use of capnography for respiratory monitoring outside ... of healthcare leaders in embracing state-of-the-art patient ... effectively patients are breathing and can alert ... By measuring the amount of carbon dioxide ...
(Date:7/10/2014)... DUBLIN , July 10, 2014 ... the addition of the "International Photonic Integrated ... - Forecasts to 2019" report to their ... The concept of photonic integration traces ... twentieth century. The promise of photonic integration went ...
(Date:7/10/2014)... 17, 2014 Using microscopic polymer light resonators ... researchers at MIT,s Quantum Photonics Laboratory have developed ... the parts-per-billion range. Optical sensors are ideal for ... signal-to-noise ratio, compact, lightweight nature, and immunity to ... had been developed before, the MIT team conceived ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Swell new sensors 2
... Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) and ... how the botulinum neurotoxin, a potential bioterrorism agent, survives ... through the human body. Their study, published February 24 ... of a neurotoxin together with its bodyguard, a protein ...
... The condensation of water is crucial to the operation of ... they are fueled by coal, natural gas or nuclear fuel. ... salty or brackish water. But there are still large gaps ... the surfaces used to turn steam back into water in ...
... 23, 2012 Springboard Enterprises has over a ... by women to potential investors and corporate partners. ... community-driven accelerator designed to fast track the growth ... healthcare IT companies from around the world. The ...
Cached Biology Technology:Disarming the botulinum neurotoxin 2Disarming the botulinum neurotoxin 3Making droplets drop faster 2Making droplets drop faster 3The Search Is On for the Next Big Life Science Innovation 2The Search Is On for the Next Big Life Science Innovation 3
(Date:7/11/2014)... from Salk Institute for Biological Studies, BGI, and ... safety and reliability of the existing targeted gene ... TALEN-HDAdV, which could significantly increased gene-correction efficiency in ... published online in Cell Stell Cell ... gene therapy. , The combination of stem cells ...
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
(Date:7/11/2014)... has demonstrated that transplantation of mesenchymal stem cells can ... mouse models of Alzheimer,s disease (AD) and improve tissue ... Few studies are reported on the therapeutic effect of ... and on the effect on oxidative injury and neurogenesis ... and her team, School of Life Sciences, Tsinghua University, ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Molecular snapshots of oxygen formation in photosynthesis 2
... Aware, Inc. (Nasdaq: AWRE ), a leading technology ... scheduled a conference call to discuss the company,s operating results ... February 3, 2011, at 5:00 p.m. Eastern Time. President and ... earnings conference call. This call is being webcast ...
... HARBIN, China, Feb. 1, 2011/PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology ... WKBT ) ("Weikang" or the "Company"), a leading ... (TCM), Western prescription and OTC pharmaceuticals and other ... of China, today announced the completion of its ...
... SANDY, Utah, Feb. 9, 2011 Qqest and M2SYS ... announced a partnership that allows Qqest to offer TimeForce ... features of biometric identification technology at their PC. ... biometric platform technology to seamlessly interface with Qqest,s ...
Cached Biology News:Aware, Inc. Announces Q4 and FY2010 Earnings Conference Call 2Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 2Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement 3Qqest Teams Up With M2SYS to Add Biometric Technology at the Desktop to TimeForce Time and Attendance System 2Qqest Teams Up With M2SYS to Add Biometric Technology at the Desktop to TimeForce Time and Attendance System 3
... Jouan RC10 series of vacuum concentrators/centrifugal evaporators ... features allied to rapid and safe concentration ... be combined with oil-free or high vacuum ... a wide selection of rotors (eliminating sample ...
... is Thermo Electron's most advanced personal gradient ... to use sophisticated onboard software and a ... to offer performance, accuracy and simplicity in ... of customer driven features built up on ...
Carrier Serum...
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
Biology Products: